地拉罗司去铁的效果怎么样？

An Italian retrospective study reported that 42.7% of patients achieved a hematological response and reduced the need for blood transfusions after receiving DFO or chelation therapy. There may be a dynamic, bidirectional regulatory mechanism between erythropoiesis and iron overload. On the one hand, ineffective erythropoiesis can lead to increased intestinal iron absorption through reduced hepcidin secretion by the liver. On the other hand, chelation treatment of iron overload can improve erythropoiesis, increase hemoglobin levels, and reduce clinical blood transfusions.

In addition to reducing blood transfusions, iron chelation therapy has additional effects against tumor proliferation. Researchers added deferasirox to the bone marrow cell culture medium of patients with myelodysplastic syndrome (MDS) and found that the viability of MDS-derived progenitor cells was significantly reduced and their cloning ability was also significantly inhibited. A study of 158 patients with serum ferritin >1000 ng/mL after hematopoietic stem cell transplantation found that 23 patients who received iron chelation therapy had a higher 5-year overall survival rate (59% vs. 34%, P = 0.008) and a lower risk of recurrence (18% vs. 41%, P = 0.012) than those who did not receive chelation therapy. It can be seen that iron chelating drugs can not only provide clinical benefits through iron removal, but also provide anti-tumor proliferation effects on certain myeloid leukemias.

(deferasirox) dispersible tablets are taken at a daily dose of 20 to 30 mg/kg, and the drug is used once a day. It has good clinical compliance, but it is expensive. In addition to chelating intracellular iron, deferasirox is also related to the prolongation of hepcidin, which can reduce iron absorption in intestinal cells, so the effect of iron removal therapy is better. For more information about deferasirox, please contact Medical Companion Travel for details.